Casdin Capital, LLC bought $11.1M of GeneDx (WGS)
Executed Jun 4, disclosed Jun 8, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Jun 8), the stock returned +24.6% (delay-adjusted); from the execution session (Jun 4), +27.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
Casdin Capital, LLC (Director) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in GeneDx Holdings Corp. (WGS). Across 2 priced purchase filings, the average 21-session return was +36.2% from execution and +32.5% from disclosure (delay-adjusted; derived). The largest single filing was $21.5M of WGS (500,000 sh across 3 lots, as filed), executed May 18.
Healthcare · GeneDx Holdings Corp., a genomics company, provides genetic testing services
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→500,000 sh across 3 lots
Exec May 18
Filed May 20 · 7:45 PM ET